Updates from DREAMM-7 and DREAMM-8

In this video, Dr Marie Vercruyssen, hematologist at the Institut Jules Bordet in Brussels, summarizes updated results from the pivotal phase III DREAMM-7 and DREAMM-8 trials presented during the 2026 annual meeting of the European Hematology Association. Both these studies are evaluating belantamab mafodotin-based regimens in patients with relapsed/refractory multiple myeloma (RRMM). The analyses presented at EHA 2026 further support the efficacy of these regimens and provide new insights into the durability and depth of responses achieved with belantamab-containing combinations.

DREAMM-7 enrolled nearly 500 RRMM patients w compared belantamab mafodotin, bortezomib and dexamethasone (BVd) with daratumumab, bortezomib and dexamethasone (DVd). Updated results confirmed the previously reported progression-free survival (PFS) benefit, with a median PFS of ~33 months in the BVd arm compared to ~15 months in the DVd arm. Among the approximately 30% of patients who achieved a complete response (CR), median PFS was not reached, highlighting the durability of deep responses. Also results for overall survival (OS) were favorable, with a median OS that was not yet reached in the BVd group versus 58 months in the standard-of-care arm. No new safety signals were identified.¹

The DREAMM-8 phase III trial randomized approximately 300 patients to receive belantamab mafodotin, pomalidomide and dexamethasone (BPd) or pomalidomide, bortezomib and dexamethasone (PVd). Median PFS remained substantially longer with BPd, at approximately 33 months compared with 11 months for PVd. Importantly, deeper responses were observed with BPd, with 28% of patients obtaining measurable residual disease negativity compared with only 6% in the control arm. In addition, one-third of patients experienced sustained responses lasting beyond 30 months.^2,3

The long-term disease control with BPd was further supported by PFS2 analyses. At the time of the analysis, the median PFS2 reached 47 months with BPd as compared to 22 months with PVd, indicating that the clinical benefit of belantamab mafodotin extends beyond treatment discontinuation and translates into prolonged disease control.⁴